Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
- 1 July 2014
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 3 (4) , 399-422
Abstract
Drugs for ultra-rare disorders (URDs) rank prominently among the most expensive medicines on a cost-per-patient basis. Many of them do not meet conventional standards for cost–effectiveness. In light of the high fixed cost of R&D, this challenge is inversely related to the prevalence of URDs. The present paper sets out to explain the rationale underlying a recent expert consensus on these issues, recommending a more rigorous assessment of the clinical effectiveness of URDs, applying established standards of evidence-based medicine. This may include conditional approval and reimbursement policies, which should be combined with a firm expectation of proof of a minimum significant clinical benefit within a reasonable time. In contrast, current health economic evaluation paradigms fail to adequately reflect normative and empirical concerns (i.e., morally defensible 'social preferences') regarding healthcare resource allocation. Hence there is a strong need for alternative economic evaluation models for URDs.Keywords
This publication has 169 references indexed in Scilit:
- CAN COST-EFFECTIVENESS ANALYSIS INTEGRATE CONCERNS FOR EQUITY? SYSTEMATIC REVIEWInternational Journal of Technology Assessment in Health Care, 2012
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying conceptsBMC Health Services Research, 2011
- Age as a Criterion for Setting Priorities in Health Care? A Survey of the German Public ViewPLOS ONE, 2011
- Development of a self-report measure of capability wellbeing for adults: the ICECAP-AQuality of Life Research, 2011
- The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based designThe European Journal of Health Economics, 2011
- Comparison of 5 Health-Related Quality-of-Life Indexes Using Item Response Theory AnalysisMedical Decision Making, 2009
- Orphan drug development is not taking offBritish Journal of Clinical Pharmacology, 2009
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Preferences for life saving programs: how the public discounts time and ageJournal of Risk and Uncertainty, 1994